Using 68Ga-FAPI PETCT Scans to Measure Inflammation in Sjgrens Syndrome and Compare With Tumor Patients

What this Trial Is About

Sjogrens syndrome SS is a chronic autoimmune disease mainly affecting the salivary and lacrimal glands, causing dryness in the mouth and eyes. It can also impact other parts of the body, leading to symptoms like fatigue and joint pain, with a risk of lymphoma in severe cases. This study aims to evaluate the use of 68Ga-FAPI PETCT imaging to assess inflammatory activity in SS and compare the inflammation patterns with those seen in tumor patients. The goal is to better guide treatment decisions by understanding how this imaging technique reflects disease activity. Participants diagnosed with SS will receive an intravenous injection of 68Ga-FAPI, a tracer used in PETCT scans to detect inflammation. The study includes two groups one with SS patients undergoing 68Ga-FAPI PETCT scans, and a control group of tumor patients also receiving the same imaging procedure. The study will measure how the tracer is taken up in affected tissues and compare uptake patterns between autoimmune inflammation and tumors. The study is non-randomized and includes adults aged 18 to 80 years. During the study, participants will undergo PETCT scans to capture images of inflammation in the glands and other tissues. Researchers will analyze the timing of optimal imaging, correlate PET findings with inflammatory markers, and compare tracer uptake between SS and tumor groups. The study will last up to three months for imaging follow-up, with close monitoring of clinical symptoms and blood tests. This approach aims to provide new insights into disease activity and help tailor future treatments for people with SS.

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT